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Sommario 
Tanti studi hanno contribuito a stabilire una stretta interazione tra il tessuto 
adiposo e il cancro in presenza di malattie metaboliche come l'obesità. Studi 
epidemiologici hanno dimostrato che i pazienti obesi hanno un rischio 
drasticamente più elevato di sviluppare il cancro. Si ritiene che questo effetto pro-
tumorale in pazienti obesi sia dovuto all'aberrante rilascio sistemico e paracrino di 
citochine pro-infiammatorie da parte delle cellule adipose, che collabora ad 
aumentare la proliferazione delle cellule tumorali e la diffusione metastatica. 
Inoltre, gli adipociti associati al cancro (CAA) possono contribuire allo sviluppo 
tumorale, fornendo un supporto metabolico all'incrementata richiesta 
bioenergetica delle cellule tumorali. 
Tuttavia, resta ancora da stabilire se un rilevante effetto pro-infiammatorio possa 
essere esercitato dal tessuto adiposo peritumorale nei pazienti non-obesi con 
cancro gastrointestinale. 
Il cancro gastrointestinale è responsabile di più morti di qualsiasi altro tipo di 
cancro. Come per altri tipi di cancro, molti studi hanno dimostrato la forte 
relazione tra neoplasie gastrointestinali e le malattie sistemiche del tessuto 
adiposo, come l'obesità e il diabete, ma quasi nulla si sa riguardo l'interazione 
locale fra le cellule tumorali gastrointestinali e il tessuto adiposo peritumorale in 
pazienti non-obesi/non-diabetici. 
Per iniziare a colmare questo vuoto abbiamo studiato se il tessuto adiposo che 
circonda tumori gastrointestinali umani possa essere alterato in termini di 
morfologia e infiltrazione infiammatoria. Specificamente abbiamo confrontato il 
tessuto adiposo peritumorale e non peritumorale (grasso viscerale distante dalla 
lesione tumorale) degli stessi soggetti per dimensioni e morfologia delle adipociti, 
numero di linfociti (cellule positive CD3, CD3 +) e macrofagi (cellule positive 
CD68, CD68 +) infiltranti. 
Abbiamo trovato che il tessuto adiposo peritumorale mostra adipocitici di 
dimensioni significativamente ridotte, e un maggiore numero di linfociti e 
macrofagi attivati. I nostri risultati forniscono evidenze cliniche a supporto del 
concetto secondo cui gli adipociti all'interfaccia tumore-stroma siano coinvolti in 
un complesso circolo vizioso organizzato dalle cellule tumorali per promuovere la 
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progressione del tumore. In particolare i nostri risultati suggeriscono che gli 
adipociti peritumorali potrebbero fornire un contributo allo sviluppo tumorale 
alimentando le richieste metaboliche di cellule cancerose e fornendo segnali 
mitogenici attraverso il rilascio paracrino di citochine pro-infiammatorie. 
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Abstract 
A large body of evidences has contributed to establish a strict association between 
adipose tissue and cancer in the contest of metabolic disorders such as obesity. 
Epidemiological studies have shown that obese patients have a drastically higher 
risk to develop cancer. This tumor-promoting role in the context of obesity is 
thought to rely mainly on the aberrant systemic and paracrine release of pro-
inflammatory cytokines by fat cells, which ultimately cooperate to boost cancer 
cell proliferation and metastatic dissemination. 
In addition, cancer associated adipocytes (CAAs) may contribute in tumor 
progression by providing a metabolic support to the aberrant bioenergetics 
demand of cancer cells.  
However, it still remains to be established whether a relevant pro-inflammatory 
effect might be exerted by peritumoral adipose tissue in non-obese patients with 
gastrointestinal cancer.  
Gastrointestinal cancers are responsible for more deaths than any other cancer in 
the body. As for other types of cancer, many studies have revealed the strong 
relationship between gastrointestinal neoplasms and systemic disorders of adipose 
tissue, such as obesity and diabetes, but almost nothing is known about the local 
interaction between gastrointestinal cancer cells and peritumoral adipocytes in 
non-obese/non-diabetic patients. 
In order to start bridge this gap we assess whether adipose tissue surrounding 
human gastrointestinal tumors might be altered in terms of adipocyte morphology 
and inflammatory infiltration. Specifically we compare peritumoral and non-
peritumoral adipose tissue (visceral fat distant from tumor lesion) for the 
adipocyte size and morphology, cell count of lymphocytes (CD3 positive cells, 
CD3+) and macrophages (CD68 positive cells, CD68+). 
We found that peritumoral adipose tissue exhibit significantly reduced adipocyte 
size and increased number of activated lymphocytes and macrophages. Our results 
provide clinical evidences in support of the emerging notion that adipocytes at the 
tumor-stroma interface participate in a highly complex vicious cycle organized by 
cancer cells to promote tumor progression. Specifically our results suggest that 
peritumoral adipocytes might provide a significant contribution to enhance tumor 
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burden by fueling cancer cell's metabolic demands and providing mitogenic 
signals via the paracrine release of pro-inflammatory cytokines. 
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Introduction 
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1.1 Tumor definition 
An irregular progress of tissue is called Neoplasm, and when it forms a mass, 
is usually referred to as a tumor (Birbrair et al, 2014) (Figure1).  
 
 
Figure 1: The step modifications of a normal tissue to cancerous tissue. A normal 
cell population can change into a population of invasive cancerous cells. The 
diagram shows five different groups of cells, which are labeled: normal, hyperplasia, 
atypical hyperplasia, carcinoma in situ, and microinvasive. The normal cells are 
arranged in a single layer to form a closed, hollow, ring. The hyperplasia is a group 
of cells that begins to divide and increase in number, forming a second and third 
layer of cells within the ring. In atypical hyperplasia, the three layers of cells have 
expanded to form a small mass of purple and blue, rapidly proliferating cells. The 
cells are no longer organized in rows, and some are even piled up on top of one 
another. In carcinoma in situ, the small mass of cells has expanded further to form a 
dense population of blue and purple, mutant cancer cells that occupies most of the 
space within the ring of normal healthy cells. In the final cell population, 
microinvasive, a rupture in the left side of the ring of healthy cells has appeared, and 
several purple, mutant cancer cells are shown spilling out from the dense mass of 
cancer cells inside. (Nature. Cell division and cancer. 2010). 
 
The World Health Organization classifies neoplasms into four important 
groups (WHO, 2014): 
• benign neoplasms: they are limited and localized and do not develop a 
cancer, 
• in situ neoplasms: possibly malignant neoplasms include carcinoma in 
situ, they are localised, do not exceed and devastate but in time may 
develop a cancer, 
• malignant neoplasms, are cancers, they exceed and devastate the 
surrounding tissue, can form metastases and when they are untreated or 
unresponsive to treatment, will became mortal, 
• Neoplasms of unknown factor.  
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1.2 Tumor Classification  
In clinical practice multiple protocols of tumor classification have been 
developed, which help optimize the choice of therapeutic approaches. These 
rely on different parameters that describe different anatomical, histological 
and molecular features of tumor parenchyma and its surrounding 
microenvironment. The most traditionally used protocols of tumor 
classification are based on the definition of three major parameters that are 
stage, grade and histological aspect of a tumor. 
 
1.2.1 Stage of tumor 
The TNM classification of malignant tumors, made and affirmed by The 
Union for International Cancer Control (UICC), describes the stage of 
a cancer by alphanumeric codes (Gospodarowicz et al, 2003 ) based on the 
size and extension of the primary tumor, its lymphatic involvement, and the 
presence of metastases (Jeffrey et al, 2013): 
 T: describes the size or the direct extent of the primary tumor (the original 
tumor): 
Tx: tumor cannot be evaluated 
Tis: carcinoma in situ 
T0: no signs of tumor 
T1, T2, T3, T4: size and/or extension of the primary tumor 
 N: degree of spread to regional lymph nodes that are involved: 
Nx: lymph nodes cannot be evaluated 
N0: tumor cells absent from regional lymph nodes 
N1: regional lymph node metastasis present 
N2: tumor spread to an extent between N1 and N3  
N3: tumor spread to more distant or numerous regional lymph nodes  
 M: presence of distant metastasis (spread of cancer from one part of the body 
to another): 
M0: no distant metastasis 
M1: metastasis to distant organs ( Haggstrom et al, 2009) 
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1.2.2 Grade of Tumor 
The grade of the cancer is based on the resemblance of the tumor to the tissue 
of origin (Abrams et al, 2010); they are low grade if they appear similar to 
normal cells and high grade if they appear poorly differentiated. 
The grade score (G1-G4) increases with the lack of cellular differentiation, it 
reflects how much the tumor cells differ from the cells of the normal tissue 
they have originated from. 
Grading systems are also different for many common types of cancer, though 
following a similar pattern with grades being increasingly malignant over a 
range of 1 to 4. If no specific system is used, the following general grades are 
most commonly used: 
 G1 Well differentiated (Low grade) 
 G2 Moderately differentiated (Intermediate grade) 
 G3 Poorly differentiated (High grade) 
 G4 Undifferentiated (High grade) 
 
1.2.3 Histology 
Cancer types can be grouped into histological categories, which include 
(Lemoine et al, 2001) (Figure 2): 
 Epithelial cells ⇨ carcinoma: 
• Adenocarcinoma: refers to a carcinoma featuring microscopic glandular-
related tissue cytology, tissue architecture, and/or gland-related molecular 
products. 
• Squamous cell carcinoma: refers to a carcinoma with observable features 
and characteristics indicative of squamous differentiation. 
• Adenosquamous carcinoma: refers to a mixed tumor containing both 
adenocarcinoma and squamous cell carcinoma, wherein each of these cell 
types comprises at least 10% of the tumor volume. 
• Undifferentiated carcinomas: refers to a heterogeneous group of high-grade 
carcinomas that feature cells lacking distinct histological or cytological 
evidence of any of the more specifically differentiated neoplasms.  
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Mesenchymal cells ⇨ sarcoma: 
• Liposarcoma is a cancer that arises in fat cells in deep soft tissue, such as 
that inside the thigh or in the retroperitoneum (Bell, 2012). Liposarcoma is 
a rare type of cancer that bears a resemblance to fat cells when examined 
under a microscope. 
• Chondrosarcoma is a cancer composed of cells derived from transformed 
cells that produce cartilage (Gelderblom H, 2008). About 30% of skeletal 
system cancers are chondrosarcomas. It is resistant to chemotherapy and 
radiotherapy. Unlike other primary bone cancers that mainly affect 
children and adolescents, chondrosarcoma can present at any age. It more 
often affects the axial skeleton than the appendicular skeleton. 
• Angiosarcoma derives from neoplastic transformation of endothelial cells 
of blood (hemangiosarcomas) or lymphatic (lymphangiosarcomas) 
vessels. 
 
 
Figure 2: Histological classification of tumor 
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1.3 Gastrointestinal tumour 
Gastrointestinal cancer represents on organs of digestion including: 
esophagus, stomach, biliary system, pancreas, small intestine, large intestine, 
rectum and anus (Figure 3, 4), frequently the diagnosis is based on endoscopy, 
followed by biopsy of ambiguous tissue. The treatment depends on the 
location of the tumor, as well as the type of cancer cell and whether it has 
invaded other tissues or spread elsewhere. These factors also determine the 
prognosis. 
 
Figure 3: Anatomic representation of a gastric stromal tumor shows and grow 
submucosal mass image with internal necrosis. (Right) Axial contrast-enhanced 
computed tomography (CECT shows a soft tissue density left upper quadrant mass. 
The origin of the mass may not be evident, except for a small projection image into 
the gastric lumen (Jeffrey, 2016). 
 
 
Figure 4: colectomy specimen. ("II Neoplasms". World Health Organization 2014). 
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In general, gastrointestinal and the accessory organs of digestion (pancreas, 
liver, and gall bladder) are responsible for more cancers and more deaths from 
cancer than any other system in the body (Bjelakovic et al, 2008; Yamada et 
al, 2009). There is significant geographic variation in the rates of different 
gastrointestinal cancers. 
 
1.3.1 Gastric cancer 
Gastric cancer is the cancer of the stomach mucosa. The main symptoms are 
heartburn, upper abdominal pain, nausea and loss of appetite (Raymond, 
2007); later symptoms are weight loss, yellowing of the skin and whites of the 
eyes, vomiting, difficulty swallowing, and blood in the stool among others. 
This cancer can propagate from the stomach to other parts of the body.  
Generally, the common cause is infection by the bacterium Helicobacter 
pylori, which represents more than 60% of cases (Chang, 2010; Amadei et al, 
2016; Chmiela et al, 2017). Other common causes include eating acid 
aliments and smoking. Genetically speaking, 10% of cases are due to 
inherited genetic factors.  
Gastric cancer is relatively common and is representing the second leading 
cause of cancer mortality in the world. Annually, more than 700,000 deaths of 
patients with gastric cancer, and almost 1,000,000 new gastric cancer cases, 
present in the entire world (Ferlay et al, 2013). But, a few of patients with 
gastric cancer are suitable for surgical treatment because of the high 
proportion of advanced tumors at the time of presentation (Carneiro, 2014). 
Anyway, this intervention remains the most important therapeutic means for 
patients with gastric cancer to achieve long-term survival. 
The chemotherapy is another way to treat stomach cancer but has no firmly 
established standard of care, because stomach cancer has not been particularly 
sensitive to drugs. If used, has usually served to reduce the size of the tumor, 
relieve symptoms of the disease and increase survival time (Scartozzi, 2007). 
Clinical researchers have explored the benefits of giving chemotherapy before 
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surgery to shrink the tumor, or as adjuvant therapy after surgery to destroy 
remaining cancer cells (Galizia, 2014). 
 
1.3.2 Colorectal cancer 
Colorectal cancer is the growth of cancer from the colon or rectum (Bibbins et 
al, 2016). Blood in the stool, a change in bowel movements, weight loss, and 
feeling tired all the time are the main symptoms of this cancer. 
Globally, colorectal cancer represents the third prevalent type of cancer, 10% 
are the newly diagnosed cancer cases and 10% are the cancer deaths (Siegal et 
al, 2012). It is more common in developed countries, where more than 65% of 
cases are found and is less common in women than men (National cancer 
institute. 2012) (Figure 5). 
 
 
Figure 5: Colon and rectum cancer deaths per million persons in 2012 
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The causes of the colorectal cancers are often old age and lifestyle factors, 
with only a small number of cases due to underlying genetic disorders. 
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Furthermore some risk factors like diet, obesity, smoking, and lack of 
physical activity. Another risk factor is inflammatory bowel disease, which 
includes Crohn's disease and ulcerative colitis (World cancer. 2014). Some of 
the inherited genetic disorders that can cause colorectal cancer include 
familial adenomatous polyposis and hereditary non-polyposis colon cancer. 
However, these represent less than 5% of cases. It typically starts as a benign 
tumor, which over time becomes cancerous. 
For colorectal cancer, the Treatments can include some combination of 
surgery, radiation therapy, chemotherapy and targeted therapy.  
 
1.4 Tumor microenvironment:  
Decades of studies have established that complex interactions with the 
anatomical microenvironment where tumor initiates may be crucial to drive 
cancer progression and metastasization. Tumor microenvironment (TME) 
comprises multiple cellular and biochemical components that may act 
promoting or mitigating cancer progression (Mbeunkui et al, 2009: Hanahan 
et al, 2011; Spaw et al, 2016) (Figure 6).  
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Figure 6:  Schematic illustration of a typical tumor microenvironment. Cancer cells 
reside in a complex microenvironment containing various supporting cells, extracellular 
matrix (ECM) and a suite of signaling molecules. These environmental components 
collectively contribute to the tumor-stromal interaction and tumor progression.  
 
These components include: 
 The cellular components: consist on the microorganisms and leukocytes, 
plus fibroblasts, pericytes, endothelial cells, neural cells and adipocytes. 
The interact with one another as well as with tumor cells in different ways.  
These components contribute to the development of an abnormal 
extracellular matrix, and then promote to tumor growth, angiogenesis, 
invasion and metastasis. 
 The non-cellular components (extracellular matrix): consist in one hand by 
the interstitial matrix formed by collagens, proteoglycans and 
glycoprotein, in the other hand the basement membrane formed by 
fibronectin, laminins, type IV collagen and linkage proteins. 
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1.4.1 Adipocytes 
Among cellular components of TME, adipocytes are emerging as crucial 
players in tumor-stroma interaction. In some tumors, cancer cell growth and/ 
Or metastasis predominantly happened in adipocyte-rich microenvironment 
(D'Esposito et al, 2016). In fact, adipocytes represent the most abundant cell 
types surrounding cancer cells.  
Adipocytes (Figure 7) derive from stromal progenitors residing within 
connective tissues and bone marrow (Majka et al, 2011). The interaction with 
tumor cells and the inflammatory signals acting within TME induces the 
conversion of stromal adipocytes into cancer-associated adipocytes, which 
display varied physiological alterations, including an increased expression of 
pro-inflammatory cytokines, growth factors, and adipokines (Dirat et al, 2011; 
Muller et al, 2013).  
Cancer-associated adipocytes may even regress to acquire fibroblast-like 
phenotype, creating a desmoplastic appearance in the stroma. Furthermore, 
the lipid-rich adipocytes in the tumor microenvironment provide an abundant 
energy supply for transformed cancer cells. In cancers growing in adipose-
rich tissues, fat stored in adipocytes may be utilized to fuel cell signalling, 
tumor growth and progression (Hardaway et al, 2014).  
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Figure 7: Components of adipose tissue (Ouchi et al, 2011) 
Adipocytes are the main cellular component of adipose tissue, and they are crucial 
for both energy storage and endocrine activity. The other cell types that are present 
are precursor cells (including pre-adipocytes); fibroblasts, vascular cells and immune 
cells, and these cells constitute the stromal vascular fraction of adipose tissue. 
Vascular cells include both endothelial cells and vascular smooth muscle cells, which 
are associated with the major blood vessels. The blood vessels in adipose tissue are 
required for the proper flow of nutrients and oxygen to adipocytes, and they are the 
conduits that allow for the distribution of adipokines. Vascular cells also secrete, and 
are responsive to, adipose tissue-secreted proteins. Other active adipose tissue 
components include macrophages and T cells, which have major roles in determining 
the immune status of adipose tissue. The fibroblast-derived extracellular matrix 
functions to provide mechanical support and excess matrix can lead to adipose tissue 
dysfunction. Factors that are secreted by these different cellular components are 
critical for maintaining homeostasis in adipose tissue and throughout the body.  
 
Adipocytes can be classified in two major subtypes morphologically and 
functionally different. Those are White and Brown adipocytes (Figure 8). 
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Figure 8: White and Brown adipose tissue. 
 
White adipocytes are enormous cells (up to 200 µm of diameter) containing a 
single, large lipid droplet covering almost the entire cytoplasm area. They are 
specialized in the storage of lipids, primarily in the form of triacylglycerol, 
which are released as free fatty acids. In adult humans, are the dominant 
subtypes. The main depots are found in subcutaneous and visceral sites 
(Figure 9).  
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Figure 9: Adipose tissue depots. Adipose tissue is mainly found in 
subcutaneous and visceral depots (Nat Rev Immunol, 2010). 
 
Visceral adipocytes are situated into the abdominal cavity between the organs 
(stomach, liver, intestines, kidneys, etc.). Visceral adipose tissue is including 
mesenteric, epididymal and perirenal white adipose tissue (Nagai et al, 2010). 
Unlike the subcutaneous adipocytes (Porter et al, 2009) visceral fat is strongly 
associated to obesity -related pathologies, like heart disease, stroke, and 
cancer (Landgraf et al, 2017). 
Brown adipocytes are morphologically distinguishable from white adipocytes, 
as they are much smaller and display multiple small lipid droplets within their 
cytoplasm (Figure 8). Brown adipocyte is frequently found in small mammals 
like rodents. In humans is abundant in new-borns and infants, but is 
drastically reduced in adults (Van Marken Lichtenbelt et al, 2009). 
Brown adipocytes exert a thermogenic function (Cannon et al, 2004). 
Recently, it has been reported the existence of a third subtype of adipose 
tissue, consisting of brown-like adipocytes residing within white adipose 
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tissue. These adipocytes have been named “beige” or “brite” (brown in white) 
adipocytes (Vitali, 2012). 
Adipose tissue functions as an endocrine organ (Kershaw et al, 2004), which 
plays a central role in regulating metabolic homeostasis. Dysfunctional 
endocrine properties of adipose tissue may result in disease-related 
alterations, including elevated release if inflammatory cytokines and increased 
infiltration of lymphocytes, macrophages, and stromal cells. The massive 
infiltration of macrophages into adipose tissue leads to chronic inflammation 
that not only modifies local metabolism, but also influences systemic energy 
homeostasis (Maury et al, 2007).  
 
1.4.2 Adipose tissue and cancer 
A large body of evidences have contributed to establish a strict association 
between adipose tissue and cancer in the contest of metabolic disorders such 
as obesity. Epidemiological studies have shown that obese patients have a 
drastically higher risk to develop cancer (Makki et al, 2013; Trevellin et al, 
2015; Divella et al, 2016). In addition, higher concentration of pro-
inflammatory cytokines has been found in the plasma of the obese-colorectal 
cancer patients compared to lean-colorectal cancer (Amor et al, 2016). These 
cytokines are likely to be released by adipose tissues located close to tumor 
cells (peritumoral adipose tissue) suggesting that obesity may exacerbate the 
tumor-promoting interaction between adipocytes and tumour cells (Conroy et 
al, 2016).  
However, it still remains to be established whether a relevant pro-
inflammatory effect might be exerted by peritumoral adipose tissue in non-
obese patients with colorectal cancer.  
In mice, it was found that adipocytes closely associated to a xenograft model 
of melanoma, exhibit an evident up-regulation of mouse cytokine including 
IL6, CXCL1, MCP1, MIP2 AND TIMP1 compared to distant non-tumoral 
adipose tissue (Wagner et al., 2012). In addition, peritumoral adipose tissue 
showed a reduced adipocyte size, vast fibrosis, increased angiogenesis and a 
dense macrophage infiltrate. Also, the CD11b+ macrophages were abundant 
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in peritumoral adipose tissue and resulted to overexpress Arg1, Nos2, Cd301, 
Cd163, Mcp1 and Vegf.  
These results drive to hypothesize that the adipose tissue adjacent to tumor is 
part of a dynamic tumoral network that involves the cancer cells and their 
neighbouring cells (Amor et al, 2016) (Figure 10).  
 
 
Figure 10. Reciprocal signalling between cancer-associated adipocytes and cancer 
cells. 
 
According to the model depicted in the figure 10, cancer cells induce 
peritumoral adipocytes toward a partial de-differentiation with reduced lipid 
content and increased secretion of free fatty acid and pro-inflammatory 
cytokines, which, in turn, promote cancer cell aggressiveness. Macrophage 
recruited into the inflammatory foci at the tumor-adipocyte interface may 
further enhance this circuit, by producing pro-inflammatory cytokines 
themselves. Peritumoral adipose tissue lose the lipogenic ability due to a 
significant reduction in both lipoprotein lipase and fatty acid synthase gene 
expression and activity.  
 
1.5 Aim of the work  
Many studies have contributed to reveal the strong relationship between 
cancer and systemic disorders of adipose tissue, such as obesity and diabetes, 
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but almost nothing is known about the local interaction between cancer cells 
and peritumoral adipocytes in non-obese/non-diabetic patients. 
In order to start bridge this gap we assess whether adipose tissue surrounding 
human colorectal tumors might be altered in terms of adipocyte morphology 
and inflammatory infiltration. Specifically we compare peritumoral and non-
peritumoral adipose tissue (visceral fat distant from tumor lesion) for the 
adipocyte size and morphology, cell count of lymphocytes (CD3 positive 
cells, CD3+) and macrophages (CD68 positive cells, CD68+). 
  
25 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2 
Materials and methods 
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2.1. Patients 
During my doctoral program until now, we have collaborated with Professor 
Giovanni De Manzoni surgeon and director of general surgery of oesophagus 
and stomach unit, at integrated university hospital of Verona. 
Specimens, including peritumoral and non-peritumoral adipose tissue, were 
extracted from colon and stomach. Samples were taken off from patient with a 
gastrointestinal cancer that had not received chemotherapy, but had 
undergone surgical intervention such as subtotal/total gastrectomy or 
resection of the rectum. At the day of a surgical intervention, peritumoral/non 
peritumoral adipose tissue was carefully micro-dissected away from the 
surrounding tumor mass and from the distant fat of the same patient. 
The peritumoral adipose tissue samples were collected from the fat very close 
to the tumor. Contrariwise, non-pertiumoral samples were taken from visceral 
fat surrounding the same organ of the tumor (either stomach or colon) but 
located distal from the tumor lesion.  The patients had undergone subtotal or 
total gastrectomy, low anterior resection of the rectum, blind resection. All 
samples were conserved in formalin for at least one week, and then fixed with 
paraffin. 
In the following part, we have the clinic card of patient, and we hide their 
names and give them a code for their privacy. 
 
2.1.1. Patients with colorectal tumor 
     P1  (29/03/1945):   
- Tumor in the left flexure of the colon, 
- Intervention 29/10/2015: resection of transverse/ flexure left with packaging 
descending-transverse end-to-side anastomosis, 
- Histological examination: less than 50% mucinous aspects of the large 
intestine with adenocarcinoma poorly differentiated G3, 
- Maximum diameter: 6.5 cm, 
- Infiltrating: the visceral wall-thickness and perivisceral fat (pT3), 
- Progress: neoplastic expansive type, 
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- Vascular and lymphatic invasion: not evident, 
- Perineural invasion: not evident, 
- Tumor budding: absent, 
- 24 pervisceral lymph-nodes free of metastases (0/24), 
- Last Follow-up 09/09/2016: patient still alive, no disease recurrence. 
 
     P2 (25/12/1936):  
- Adenocarcinoma ileocecal, 
- Intervention 25/11/2015: blind resection with anastomosis packaging ileum-
ascending lateral chest, 
- Histological examination: mucinous aspects of the large intestine with 
adenocarcinoma poorly differentiated G3, 
- Maximum diameter: 3.5 cm, 
- Infiltrating: the visceral wall-thickness, the perivisceral fat and serous (pT4), 
- Progress: neoplastic expansive type, 
- Vascular and lymphatic invasion: not evident, 
- Perineural invasion: not evident, 
- Tumor budding: present, 
- Last Follow-up: the patient died of postoperative complications. 
 
P3 (30/09/1923):  
- Adenocarcinoma of the rectum, 
- Intervention 03/09/2016: low anterior resection with colorectal anastomosis 
termino-lateral and cholecystectomy, 
- Histological examination: Cholecystitis free from neoplastic infiltration with 
chronic framework and adenomyosis foci, 
- Moderately differentiated adenocarcinoma of the large intestine, with <50% 
of aspects mucinous,  
- Infiltrating tumor: the bowel full thickness , the perivisceral fat, 
- 17 lymph nodes free of metastases + 6 perivisceral lymph nodes free of 
metastases (N tot 0/23), 
- Last Follow-up in November 2016: the patient still alive does not relapse 
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2.1.2 Patients with gastric tumor 
 
P4  (10/08/1941): 
- Adenocarcinoma gastric antrum, 
- Intervention 11/10/2015: subtotal gastrectomy with lymphadenectomy D1, 
and packaging of gastro-jejunal anastomosis, cholecystectomy, resection of 
liver metastases IV segment, 
- Histological examination: Gastric adenocarcinoma, tubular section 
moderately differentiated,  
- The maximum diameter: 5 cm, 
- Infiltrating tumor: the visceral wall-thickness with extension to serous tunic 
and packet nodal epigastric (pT4), 
- Carcinomatosis vascular-lymphatic: present, 
- Carcinomatosis perineural: present, 
- Chronic cholecystitis, cholelithiasis, free of neoplastic involvement, 
- Metastases in seven out of thirteen lymph nodes of the small curve (7/13), in a 
lymph node right gastroepiploic artery (1/1), in two out of five gastric artery 
lymph nodes left (2/5), an artery lymph node gastroepiploic left free of 
metastases (0/1) (N tot 10/20), 
- Hepatic metastases of adenocarcinoma, 
- Last Follow-up April 2016: hepatic recurrence. 
P5 (08/08/1941): 
- Adenocarcinoma gastric antrum, 
- Intervention 20/11/2015:subtotal gastrectomy with lymphadenectomy D1, and 
packaging of gastro-jejunal anastomosis, removal of three diaphragmatic 
nodules and macroscopic residual of transverse mesocolon, 
- Histological examination: Gastric adenocarcinoma type mucinous, poorly 
differentiated, 
- The maximum diameter of 6.5 cm, 
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- Infiltrating tumor: the visceral wall-thickness, the perivisceral fat and serous 
(pT4), 
- Carcinomatosis vascular-lymphatic: present, 
- Carcinomatosis perineural: present,  
- Metastases in two out of four perivisceral lymph nodes (2/4), 
- Lymph node metastasis and perilinfonodali in one in eight lymph nodes of the 
small curve (2/8), in six gastroepiploic left artery lymph nodes (6/6), in three 
gastroepiploic left artery lymph nodes (3/3) in two lymph nodes (2/2), in three 
out of four lymph nodes (3/4), in seven out of ten left gastric artery lymph 
nodes (7/10) (N tot 25/37), 
- Fragments fibromuscolar with infiltrating adenocarcinoma, 
- Omentum free of neoplastic involvement, 
- Last Follow-up in August 2016: living patient 
P6  (30/05/1946): 
- Adenocarcinoma of the lesser curvature of the stomach 
- Intervention 17/02/2016: total gastrectomy and D2 lymphadenectomy 
abdominal extended to para-aortic, 
- Histological examination: Gastric adenocarcinoma, poorly differentiated, 
- The maximum diameter: 6 cm, 
- Infiltrating tumor: the visceral wall-thickness with extension to serous tunic 
(pT4), 
- Carcinomatosis vascular-lymphatic: present, 
- Carcinomatosis perineural: present, 
- Perivisceral lymph node metastases in three (3/3), 
- Omentum free of neoplastic involvement, 
- Last Follow-up in February 2017: the patient still alive does not relapse. 
 
P7 (23/10/1948): 
- Adenocarcinoma gastric antrum, 
- Intervention 02/11/2016: subtotal gastrectomy with lymphadenectomy D1, 
and packaging of gastro-jejunal anastomosis, cholecystectomy, 
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- Histological examination: Gastric adenocarcinoma, mixed (tubular and 
mucinous), moderately differentiated, 
- The maximum diameter: 3 cm, 
- Infiltrating tumor: the visceral wall-thickness with extension to serous tunic 
(pT4), 
- Carcinomatosis vascular-lymphatic: present 
- Carcinomatosis perineural: not evident 
- A lymph node metastases with adenocarcinoma (1/2), two localization of 
lymph nodes with adenocarcinoma (2/2), two gastroepiploic artery lymph 
nodes free of metastases (0/2) (N tot 3/6), 
- Omentum free of tumor localization, 
- Chronic cholecystitis, 
- Last Follow-up in November 2016: the patient still alive, followed by 3 cycles 
adjuvant radiotherapy (45Gy) with radio sensitizing chemotherapy with 
capecitabine interrupted for severe thrombocytopenia, 
 
P8 (04/08/1939): 
- Gastric Adenocarcinoma of the small curve, 
- Intervention 22/03/2016: total gastrectomy with D2 lymphadenectomy and 
packaging of gastro-jejunal anastomosis, 
- Histological examination: Gastric adenocarcinoma, Tubular and poorly 
cohesive, moderately-poorly differentiated, Mixed (intestinal or diffuse), 
- The maximum diameter: 4 cm, 
- Infiltrating the visceral wall-thickness and adipose tissue perivisceral coming 
throughout the vicinity, apparently without infiltrate the tunica serosa (pT3), 
- Carcinomatosis vascular-lymphatic: present, 
- Carcinomatosis perineural: present, 
- Four perivisceral lymph nodes (small curve) and 3 lymph nodes perivisceral 
(big curve), free of metastases (0/7), five right pericardial lymph nodes (0/5), 
nine claims pericardial lymph nodes (0/9), seventeen lymph nodes of the 
small curve (0/17) ten lymph nodes of the short gastric vessels (0/10), 
fourteen gastroepiploic left artery lymph nodes (0/14), twenty-two artery 
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gastroepiploic right lymph nodes (0/22), thirteen lymph nodes (0 / 13), eleven 
left gastric artery lymph nodes (0/11), seventeen common hepatic artery 
lymph nodes (0/17), four nodes of the celiac trunk (0/4), eight of the splenic 
artery proximal lymph nodes (0 / 8), a splenic artery distal lymph node (0/1), 
a hepatic artery lymph own (0/1) and four lymph nodes (0/4) free of 
metastases. 
- Flap of momentum free of neoplastic involvement and lymph node 
metastasis-free (0/1) (N tot 0/144). 
- Last Follow-up in July 2016: the patient still alive does not relapse. 
 
All samples were conserved and fixed in 10% of formalin solution for at least 
one week then they were included in paraffin, once the tissue is embedded in 
paraffin, it is stable for many years. 
 
2.2 Paraffin inclusion: 
In this procedure, the tissue was dehydrated through a series of graded ethanol 
baths to displace the water, and then was infiltrated with paraffin, the 
technique is as follows:  
• wash the tissue with the phosphate buffered saline solution (PBS): to remove 
excess of formalin, 
•  dehydrate with different concentrations of ethyl alcohol in ascending scale 
70°, 80°, 90°, and overnight at 100°: to remove the aqueous component, 
which does not allow the entry of the paraffin in the tissue, 
• transfer the tissue in xylene: to permit absolute alcohol replacement, 
• Infiltration with paraffin at 58- 60°: to replace the xylene inside the 
histological piece with the paraffin, his hardness of the solid paraffin allows 
us to realize the histological sections. 
The inclusion in paraffin was carried out at room temperature. After that, the 
cooled block of paraffin was ready for microtome cut, and to slice the piece at 
7 mm of thickness. Then we leave slide for a while to dry in the room.  
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2.3 Hematoxylin and eosin 
Hematoxylin and eosin stain are still essential for recognizing various tissue 
types and the morphologic changes that form the basis of contemporary 
cancer diagnosis. The stain has been unchanged for many years because it 
works well with a variety of fixatives and displays a broad range of 
cytoplasmic, nuclear, and extracellular matrix features. 
Hematoxylin has a deep blue-purple color and stains nucleic acids by a 
complex, incompletely understood reaction. Eosin is pink and stains proteins 
nonspecifically. In a typical tissue, nuclei are stained blue, whereas the 
cytoplasm and extracellular matrix have varying degrees of pink staining 
(Fischer et al, 2008).  
Well-fixed cells show considerable intranuclear detail. Nuclei show varying 
cell-type- and cancer-type-specific patterns of condensation of 
heterochromatin (hematoxylin staining) that are diagnostically very important. 
Nucleoli stain with eosin. If abundant polyribosomes are present, the 
cytoplasm will have a distinct blue cast. The Golgi zone can be tentatively 
identified by the absence of staining in a region next to the nucleus. Thus, the 
stain discloses abundant structural information, with specific functional 
implications. Hematoxylin, generally without eosin, is useful as a counterstain 
for many immunohistochemically procedures. 
This protocol describes hematoxylin and eosin staining of tissue. 
Eosin Y (1% aqueous solution; Sigma), Hematoxylin, Mayer’s (Sigma), 
Ethanol (95%, 100%), Mounting medium (Entellan, Sigma), Xylene, 
Coverslips. 
To hydrate the tissue, the sections of paraffin embedded tissues are fixed in 
xylene, then in alcohol and finally in distilled water.  
We Dip the slide into a Mayer’s hematoxylin solution and agitate for 30-
40sec. 
We Rinse the slide in H2O for 1 min and we estimate the staining intensity at 
this point. 
We stain the slide with 1% eosin Y solution for 10-30 sec with agitation. 
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We dehydrate the sections with one of change of 80% alcohol, one change of 
95%, and two changes of 100% alcohol for 2min each. Some colorimetric 
substrates dissolve in alcohol. 
We extract the slides from the alcohol with two changes of xylene for 5min. 
We add one or two drops of mounting medium and we cover it with a 
coverslip. 
 
2.4 Immunohistochemistry 
The immunohistochemistry technique is able to identify specific molecules or 
structures of the intra and extra cellular compartment, is based on the 
principle of antigen-antibody conjugation, then in addition with detection 
systems (enzymatic) that the reaction took place to make visible at the 
microscope. In our case the reaction between antigen-antibody is detected 
with immunoperoxidase method and the sections will be observed under the 
microscope Olympus BX51, equipped with KY-F58 CCD camera (Merigo et 
al, 2008). 
General Immunostaining protocol for paraffin peritumoral adipose tissue 
section is the follow: 
- Deparaffinize the tissues as outlined below: 
o xylene : 2 changes, 5 min each 
o 100% alcohol: 2 changes, 2 min each 
o 95% alcohol: 2 washes, 2 min each 
o 70% alcohol: 2 changes, 2 min each 
o distilled H20: 1 change, 2 min 
- Antigen retrieval:  antigens can become masked during the preparation of 
the tissue.  In our case, we use the sodium citrate buffer method (pH 6.0) in 
microwave for a total of 15 min. Slides must be cooled for 20-30 min before 
proceeding to immunostaining. Wash sections in PBS, 3 changes, 5 min each. 
- Block endogenous peroxidase activity with 3% hydrogen peroxide (H2O2) in 
PBS for 10 min. Presence of endogenous peroxidase enzymes in the tissue can 
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severely limit the interpretation of immunoperoxidase staining. Wash slides in 
double distilled water for 5 min once. 
- Rinse in PBS for 5 min with two changes.  
- Block nonspecific binding with 5% normal goat or rabbit serum for 20 min 
at room temperature. 
- Incubate with specific primary and secondary antibodies and precede for the 
detection with 3, 3’-diaminobenzidine (DAB) solution (Menon et al, 2015). 
 
Antibody used in this study 
CD68 (anti-macrophage): is a macrophage marker frequently used in many 
studies. The sections are incubated overnight with monoclonal mouse anti-
human CD68 (1: 150, Thermo scientific).  
Secondary Antibody: Incubate sections in Goat anti-mouse antibody (1: 200) 
diluted in blocking solution for 30 min. 
Counter stain with hematoxylin and dehydrate sections as follows: 
- Hematoxylin: 30-40 sec 
- PBS: 2 changes, 3 min 
- 70% Ethanol: 1 change, 2 min. 
- 95% Ethanol: 1 change, 2 min. 
- 100% Ethanol: 1 change, 2 min. 
- Xylene, 3 changes, 2 min. 
 Mount section with Entellan and coverslip. 
 
CD3 (anti-lymphocytes): is a polyclonal rabbit anti-human (ready to use, 
Thermo scientific), the sections are incubated overnight. 
Secondary Antibody: Incubate sections in Goat anti-rabbit antibody (1: 200) 
diluted in blocking solution for 30 min. 
Counter stain with hematoxylin and dehydrate sections as follows: 
- Hematoxylin: 30-40 sec 
- PBS: 2 changes, 3 min 
- 70% Ethanol: 1 change, 2 min. 
- 95% Ethanol: 1 change, 2 min. 
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- 100% Ethanol: 1 change, 2 min. 
- Xylene, 3 changes, 2 min. 
 Mount section with Entellan and coverslip. 
 
2.5 Microscope: 
Immunoreactivity was studied with light microscopy under bright-field 
illumination. Quantitative evaluation was based on counts of CD68-CD3 and 
cells, as well as densitometric analysis of the immunosignal intensity. 
For our analysis we have using a JVC CCD KY-F58 digital camera connected 
to the microscope and the image analysis software Image Pro Plus 4.5 (Media 
Cybernetics, Silver Spring, MD). 
For each adipocyte, the area was measured. The Ferret’s diameter (or Ferret 
Diameter FD) is a measure of an object size along a specified direction. 
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3.1 Adipocyte size and morphology 
A 
 
B 
   a   b  
  c   d    
                    Non peritumoral                                      peritumoral 
Figure 11: A: The histogram shows mean values ± SE of adipocyte size in 
peritumoral/non peritumoral adipose tissue, * p<0,05. B: The section of non-
peritumoral (a and c) and peritumoral (b and d) adipose tissue stained with 
Hematoxylin Eosin.  Red lines are indicative of the method used to measure 
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adipocyte size. On each slide, the contour of every adipocyte was manually lined and 
the inner area was measured using ImageJ software. Scale bar: 25um; all the other 
images are at the same magnification (20X). 
 
The mean size was 45±4 mm for non peritumoral adipocytes and 30±1,9 mm 
for peritumoral adipocytes (p=0.04, Student t-test) (Figure 11 A). Peritumoral 
adipocytes were significantly smaller than their normal (non peritumoral) 
counterparts (Figure11 ,B).  
The adipocyte in non peritumoral fat (a,c) was characterized by a polyhedral 
and homogenous aspect while peritumoral adipocytes (b,d) were 
morphologically heterogenic.  
There was no difference in the total number of adipocytes between non-
peritumoral and peritumoral adipose tissue groups (data not shown). 
 
3.2 Lymphocyte T cells /CD3+ 
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B 
a b                        
c d                
Non peritumoral                                                 peritumoral 
Figure 12: A: The histogram show mean values ± SE of lymphocyte cells T 
activated in peritumoral/non peritumoral adipose tissue, **p<0,01. B: sections of 
adipose tissue non peritumoral (a,c) and peritumoral (b,d) with 
CD3+immunohistochemistry. Black arrows indicate labeled lymphocyte cells. Scale 
bar: 25um; all the other images are at the same magnification (40X). 
 
The number of activated CD3+ T cells lymphocytes (Figure 12) were much 
higher in peritumoral tissue (38,8±1,8 cells count) than in non peritumoral 
adipose tissue (13,8±3,3; P=0.009  Student’s t test).  
The lymphocytes infiltrated in peritumoral fat (Figure 12B, b and d) were 
mainly grouped in clusters of highly dense cellularity.  
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3.3 Macrophage /CD68+ 
A 
 
B 
a b                              
c d 
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Figure 13: A: The histogram shows mean values ± SE of macrophage cells activated 
in peritumoral/non peritumoral adipose tissue, ***p<0,001. B: sections of adipose 
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tissue peritumoral and non peritumoral with CD68+immunohistochemistry. Black 
arrow indicates labelling macrophage cells. B: sections of adipose tissue non 
peritumoral (a,c) and peritumoral (b,d) with CD68+immunohistochemistry. Black 
arrow indicates labelling macrophage cells. Scale bar: 25um; all the other images are 
at the same magnification (40X). 
 
In peritumoral fat, a higher number of CD68+ macrophages were found 
(61,1±4,8 cells count activated) compared to non peritumoral adipose tissue 
(9,7±1,2 cells count activated; P=0,00026 Student’s t test).  
As for activated lymphocytes, CD68+ macrophages were organized in dense 
clusters surrounding adipocytes, while in the non peritumoral adipose tissue 
(b.d) the presence of these cells were extremely scarce and scattered around 
the adipocytes.   
 
3.4 Macrophage Vs Lymphocytes in peritumoral 
adipose tissue  
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B 
a  b  
c  d  
                    CD68                                                                 CD3 
Figure 14: A: The histogram show mean values ± SE of macrophage and 
lymphocytes cells activated in peritumoral adipose tissue, *p<0,05. B: sections of 
adipose tissue peritumoral with CD68+ and Cd3+ immunohistochemistry. Black 
arrows indicate labelling macrophage and lymphocyte cells. B: sections of adipose 
tissue peritumoral with macrophage activation (a,c), (b,d) sections of adipose tissue 
peritumoral with lymphocytes. Scale bar: 25um; all the other images are at the same 
magnification (40X). 
 
In literature, in the tumor microenvironment, the macrophages comprise the 
dominant portion of the leukocyte population (Wagner et al, 2012). We found 
that in peritumoral adipose tissue, the number of activated macrophages 
(Cd68+) was almost double the number of lymphocytes (Cd3+). Specifically, 
macrophages were 61,11±4,8/field, while lymphocytes were 38,8±1,8 
(p=0,04).  
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Cancer associated adipocytes (CAAs) may contribute in tumor progression by 
multiple ways. First, peritumoral adipocytes have been shown to provide a 
metabolic support to the aberrant bioenergetics demands of cancer cells.  The 
adipocyte-rich tissue surrounding tumor cells offers an easily accessible 
reservoir of lipids. In vitro experiments demonstrate that secreted paracrine 
signals from cancer cells induce lipolysis in adipocytes, causing them to 
release free fatty acids (Dirat B. 2011). In human and animal models of 
cancer, body composition evaluation and morphological analysis reveals 
adipose atrophy and presence of smaller adipocytes. This fat loss occurs in 
both visceral and subcutaneous depots. In addition, increased lipolysis and fat 
oxidation, decreased lipogenesis, impaired lipid deposition and adipogenesis, 
as well as browning of white adipose tissue may underlie adipose atrophy in 
cancer (Ebadi et al, 2014). In animal model of melanoma, it has been reported 
that peritumoral adipocytes have reduced size and extensive fibrosis (Wagner 
et al, 2013). 
We found analogous results in human gastrointestinal cancer. Adipocytes 
surrounding either gastric or colorectal primary tumors display a significantly 
reduced size compared to adipocytes located distal from tumor lesion, which 
is likely the result of an increased lipolysis. Nevertheless, all adipocytes 
surrounding tumors still maintained a white adipocytes-like morphological 
phenotype, with a single, large lipid droplet covering almost the entire 
cytoplasm area. 
On the other hand, peritumoral adipose tissue may contribute to tumor growth 
by biochemical interactions at the interface with cancer cells. Tumor invades 
stromal compartments that are rich in adipose tissue, and adipocytes function 
as endocrine cells to critically shape the tumor microenvironment. Multiple 
studies in the last decades have investigated the epidemiological association 
between cancer and metabolic and adipose tissue-related pathologies, such as 
obesity and diabetes (Park et al, 2014). These studies converged to establish 
the notion that metabolic disorders of adipose tissue, especially obesity, 
strongly contribute to tumor initiation and progression. However, the 
underlying mechanisms linking obesity to neoplastic diseases remain poorly 
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understood. Adipose tissue has long been considered a mechanically 
supportive storage of energy in the form of triglycerides. Nevertheless, it is 
currently recognized as one of the most important endocrine organs, which 
play a leading role in regulating interactions between metabolic and immune 
systems (Stern et al, 2016). Several lines of evidences suggest that the tumor 
promoting role of adipose tissue relies, at least in part, on systemic and 
paracrine release of cytokines by fat cells (Park et al, 2011), which cooperate 
to boost cancer cell proliferation and metastatic dissemination. The endocrine 
function of adipose tissue is alternated in obesity and the aberrant systemic 
release of cytokines by hypertrophic adipocytes has been extensively 
investigated as one of the major causes of the increased tumor burden in obese 
patients.  The paracrine release of cytokines by peritumoral adipocyte have 
also been occasionally described and suggested as a potential modular of 
tumor biology. But, again, these few studies are limited to obese patients 
(Gnerlich et al, 2013), and are mainly aimed at identify microregional 
differences in tumor-promoting cytokine production between adipose sites 
nearby and distal from primary tumors in the context of obesity. 
Our major aim here was to start assessing whether also in non-obese patients, 
peritumoral adipocytes may show any signs of increased inflammation, likely 
indicative of an increased release of pro-inflammatory cytokines at tumor-
adipose tissue interface. We focused on gastrointestinal cancer since it is one 
of the most lethal neoplasms and assessed the frequency of activated 
lymphocytes and macrophages in comparison with non-peritumoral fat, based 
on the immunohistochemically staining with two respective highly specific 
markers that are CD3 for lymphocytes and CD68 for macrophages. Cd3 is 
known to be linked to the membranes of all mature T-cells, although it does 
appear to be present in small amounts in Purkinje cells (Amicarella et al, 
2015). This specificity combined with the presence of CD3 at all stages of T-
cell development, makes it a useful immunohistochemical marker for T-cells 
in tissue sections, and may hold an important key to unlocking effective 
cancer immunotherapy. Our results demonstrate that the level of lymphocytes 
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infiltrates in peritumoral fat is much higher than in non-peritumoral fat in 
gastrointestinal cancer.  
The Accumulation of T cells in adipose tissue precedes macrophage 
infiltration causing a chronic low-grade inflammation (Quattromoni 2012). 
CD68+ cells were highly enriched in peritumoral adipose tissue. Generally, 
the macrophages are the dominant leukocyte population found in the tumor 
microenvironment. Accumulating evidence suggests that this tumor-
associated macrophage actively promote all aspects of tumor initiation, 
growth, and development.  
In conclusion, our results provide clinical evidences in support of the 
emerging notion that adipocytes at the tumor-stroma interface participate in a 
highly complex vicious cycle organized by cancer cells to promote tumor 
progression. Specifically our results suggest that peritumoral adipocytes might 
play a significant contribution to enhance tumor burden by fueling cancer 
cell's metabolic demands and providing mitogenic signals throughout the 
paracrine release of pro-inflammatory cytokines. 
.   
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